Novel Peptide Mimetic Inhibitors of Hepatitis C Serine Protease Derived from Isomannide
Hepatitis C (HCV) infection is a cause of chronic liver disease such as cirrhosis, carcinoma, or liver failure, and the current therapy is effective in only 50% of patients. Serine proteases, which are present in HCV, are the most studied class of proteolytic enzymes, and are a primary target in the drug development field. In this paper, we describe the synthesis and biological studies of a novel class of peptide mimetic compounds as potential HCV serine protease inhibitors.
Copyright © 2009, Georg Thieme Verlag Stuttgart
Georg Thieme Verlag Stuttgart
Barros, Thalita G.; Pinheiro, Sergio; Williamson, John S.; Tanuri, Amilcar; Pereira, Helena S.; Brindeiro, Rodrigo M.; Neto, José B. A.; Antunes, Octavio A.C.; and Muri, Estela M.F., "Novel Peptide Mimetic Inhibitors of Hepatitis C Serine Protease Derived from Isomannide" (2009). Office for Research Publications and Presentations. 36.